loading
Schlusskurs vom Vortag:
$7.25
Offen:
$7.28
24-Stunden-Volumen:
701.10K
Relative Volume:
0.17
Marktkapitalisierung:
$1.54B
Einnahmen:
$557.51M
Nettoeinkommen (Verlust:
$-35.71M
KGV:
-40.78
EPS:
-0.18
Netto-Cashflow:
$15.50M
1W Leistung:
+2.03%
1M Leistung:
-3.21%
6M Leistung:
-16.99%
1J Leistung:
-8.29%
1-Tages-Spanne:
Value
$7.18
$7.40
1-Wochen-Bereich:
Value
$7.17
$7.43
52-Wochen-Spanne:
Value
$6.00
$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name
Firmenname
Biocryst Pharmaceuticals Inc
Name
Telefon
919-859-1302
Name
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
Mitarbeiter
580
Name
Twitter
@biocrystpharma
Name
Nächster Verdiensttermin
2025-02-24
Name
Neueste SEC-Einreichungen
Name
BCRX's Discussions on Twitter

Vergleichen Sie BCRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
BCRX
Biocryst Pharmaceuticals Inc
7.34 1.53B 557.51M -35.71M 15.50M -0.18
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
142.98 63.86B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.46 41.80B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.2282 40.88B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.09 22.98B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
448.00 19.53B 3.08B 1.24B 1.07B 25.61

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-15 Fortgesetzt TD Cowen Buy
2025-10-01 Herabstufung Evercore ISI Outperform → In-line
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2025-02-25 Eingeleitet Wedbush Outperform
2023-11-20 Fortgesetzt JP Morgan Overweight
2023-09-18 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-08-04 Hochstufung Jefferies Hold → Buy
2023-07-13 Hochstufung BofA Securities Neutral → Buy
2023-02-22 Hochstufung Needham Hold → Buy
2022-11-02 Hochstufung Evercore ISI In-line → Outperform
2022-08-05 Herabstufung Evercore ISI Outperform → In-line
2022-08-05 Herabstufung Oppenheimer Outperform → Perform
2022-04-18 Herabstufung Barclays Overweight → Equal Weight
2022-04-11 Herabstufung BofA Securities Buy → Neutral
2021-12-10 Eingeleitet Oppenheimer Outperform
2021-08-06 Herabstufung Jefferies Buy → Hold
2021-08-03 Eingeleitet Cantor Fitzgerald Overweight
2021-03-01 Eingeleitet Cowen Outperform
2020-09-29 Fortgesetzt JP Morgan Overweight
2020-06-17 Eingeleitet BTIG Research Neutral
2020-05-05 Hochstufung Barclays Equal Weight → Overweight
2019-11-15 Hochstufung BofA/Merrill Neutral → Buy
2019-05-24 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2018-11-16 Fortgesetzt Piper Jaffray Overweight
2018-08-08 Fortgesetzt JP Morgan Overweight
2018-07-17 Hochstufung BofA/Merrill Underperform → Neutral
2018-06-22 Eingeleitet Seaport Global Securities Neutral
2018-01-02 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2017-12-20 Eingeleitet Barclays Equal Weight
2017-09-15 Eingeleitet RBC Capital Mkts Sector Perform
2017-09-06 Hochstufung JP Morgan Neutral → Overweight
2017-09-06 Hochstufung Jefferies Hold → Buy
2017-02-16 Eingeleitet Ladenburg Thalmann Buy
2016-08-12 Hochstufung Piper Jaffray Neutral → Overweight
2016-08-04 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 Bestätigt FBR Capital Outperform
2016-02-09 Herabstufung JP Morgan Overweight → Neutral
2016-02-09 Herabstufung Needham Buy → Hold
Alle ansehen

Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten

pulisher
06:48 AM

Will BioCryst Pharmaceuticals Inc. stock maintain growth storyGlobal Markets & Reliable Intraday Trade Plans - newser.com

06:48 AM
pulisher
05:13 AM

Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Momentum Check & Smart Swing Trading Techniques - newser.com

05:13 AM
pulisher
04:40 AM

Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutEarnings Risk Summary & Real-Time Price Movement Reports - newser.com

04:40 AM
pulisher
01:35 AM

What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackJuly 2025 Trade Ideas & Smart Money Movement Alerts - newser.com

01:35 AM
pulisher
12:53 PM

Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Short Interest & Verified Technical Signals - newser.com

12:53 PM
pulisher
Oct 30, 2025

Will BioCryst Pharmaceuticals Inc. stock attract ESG investorsMarket Sentiment Summary & Fast Exit/Entry Strategy Plans - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolutionWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

# BioCryst’s SWOT analysis: stock positioned for growth amid HAE market expansion - Investing.com

Oct 30, 2025
pulisher
Oct 29, 2025

BioCryst Pharmaceuticals (BCRX) Price Target Increased by 19.59% to 21.51 - Nasdaq

Oct 29, 2025
pulisher
Oct 29, 2025

BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com

Oct 29, 2025
pulisher
Oct 28, 2025

Why BioCryst Shares Plunged - AOL.com

Oct 28, 2025
pulisher
Oct 28, 2025

Aug Shorts: Why hedge funds are buying BioCryst Pharmaceuticals Inc. stockTrade Entry Report & Weekly Stock Performance Updates - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

When is the best time to exit BioCryst Pharmaceuticals Inc.July 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - sharewise.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will BioCryst Pharmaceuticals Inc. stock outperform international peersPortfolio Update Report & AI Optimized Trading Strategy Guides - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Monday - MarketBeat

Oct 27, 2025

Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$46.17
price up icon 4.31%
drug_manufacturers_specialty_generic RDY
$13.32
price down icon 0.96%
$22.65
price up icon 0.38%
$10.39
price up icon 0.34%
$139.31
price up icon 0.92%
$448.00
price down icon 1.13%
Kapitalisierung:     |  Volumen (24h):